Skip to main content

Table 4 Outcomes of TAE for sporadic and tuberous sclerosis-related AMLs

From: Efficacy of prophylactic selective arterial embolization for renal angiomyolipomas: identifying predictors of 50% volume reduction

  Sporadic aTSC ALL P-value
bAMLs, n 15 35 50  
Mean volume reduction rate, % (±SD) 72.9 (±21.5) 63.5 (±25.2) 66.0 (±24.4) 0.27
Regrowth, n (%) 3 (20.0%) 11 (31.4%) 14 (28.0%) 0.41
Aneurysm ≥5 mm before TAE, n (%) 2 (13.3%) 17 (48.6%) 19 (38%) 0.019
Aneurysm ≥5 mm after TAE, n (%) 0 (0%) 1 (2.9%) 1 (2.0%)  
  1. aTSC tuberous sclerosis, bAML angiomyolipomas